2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, Non-Biological Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1629 Phase I trial of GCN2 activator HC-7366 in relapsed/refractory acute myeloid leukemia: Feasibility of targeting integrated stress response with clinical and pharmacodynamic activity in TP53mut disease

Dany Nassar, MD, Ashley G. Rodriguez2, Sean M Post3, Courtney DiNardo, MD, MSCE4, Yesid Alvarado Valero, MD5, Naval Daver, MD6, Maro Ohanian, DO7, Hussein Ali Abbas, MD, PhD8, Alexandre Bazinet, MD, MSc9, Kelly Sharon Chien, MD10, Danielle Hammond, MD11, Wei Ying Jen, BM BCh, FRCPath12, Nicholas Short, MD13, Nandita Bose14, Dhamina Karim, MD, MPH15, Jeremy Drees, PhD16, Eric Lightcap, PhD17, Ben Harrison, MS18, Ashley LaCayo19, Anissa SH Chan20, Kathryn Bieging-Rolett, PhD21, Michele Gargano22, Richard Huhn, MD23, David McCue24, Duyen Nguyen, MD25, Allison Pike26, Rashmi Kanagal-Shamanna, MD27, Hagop Kantarjian, MD28, Guillermo Garcia-Manero, MD29, Farhad Ravandi, MD30, Abhishek Maiti, MBBS31
1 UT MD Anderson Cancer Center, Houston, TX, United States
2 UT MD Anderson Cancer Center, Houston, TX, United States
3 UT MD Anderson Cancer Center, Houston, TX, United States
4 UT MD Anderson Cancer Center, Houston, TX, United States
5 UT MD Anderson Cancer Center, Houston, TX, United States
6 UT MD Anderson Cancer Center, Houston, TX, United States
7 UT MD Anderson Cancer Center, Houston, TX, United States
8 UT MD Anderson Cancer Center, Houston, TX, United States
9 UT MD Anderson Cancer Center, Houston, TX, United States
10 UT MD Anderson Cancer Center, Houston, TX, United States
11 UT MD Anderson Cancer Center, Houston, TX, United States
12 UT MD Anderson Cancer Center, Houston, TX, United States
13 UT MD Anderson Cancer Center, Houston, TX, United States
14 HiberCell, Inc., Roseville, MN, United States
15 HiberCell, Inc., Roseville, MN, United States
16 HiberCell, Inc., Roseville, MN, United States
17 HiberCell, Inc., Roseville, MN, United States
18 HiberCell, Inc., Roseville, MN, United States
19 HiberCell, Inc., Roseville, MN, United States
20 HiberCell, Inc., Roseville, MN, United States
21 HiberCell, Inc., Roseville, MN, United States
22 HiberCell, Inc., Roseville, MN, United States
23 Planet Pharma, Deerfield, IL, United States
24 UT MD Anderson Cancer Center, Houston, TX, United States
25 UT MD Anderson Cancer Center, Houston, TX, United States
26 UT MD Anderson Cancer Center, Houston, TX, United States
27 UT MD Anderson Cancer Center, Houston, TX, United States
28 UT MD Anderson Cancer Center, Houston, TX, United States
29 UT MD Anderson Cancer Center, Houston, TX, United States
30 UT MD Anderson Cancer Center, Houston, TX, United States
31 UT MD Anderson Cancer Center, Houston, TX, United States

Introduction: Pts with acute myeloid leukemia (AML) with TP53mut or erythroid differentiation have poor outcomes. Integrated stress response (ISR) has been reported to be an actionable pathway in such AML as well as to overcome venetoclax (VEN) resistance. HC-7366 is a novel, oral, highly selective and potent activator of general control nonderepressible 2 (GCN2) kinase, a core regulator of the integrated stress response (ISR). Benefit of GSPT1 degraders is mediated via downstream activation of GCN2. Leukemic stem cells (LSC) and erythroblasts exhibit high basal ISR signaling and are particularly sensitive to ISR hyperactivation by HC-7366, promoting p53-independent apoptosis. We hypothesized that HC-7366 would be active in R/R AML and conducted an investigator-initiated trial.

Methods: Pts with R/R AML or MDS/AML refractory to prior standard therapies were treated on this phase 1b dose escalation trial of HC-7366 with standard inclusion and exclusion criteria (NCT06285890). Primary objectives were safety and tolerability, and secondary and exploratory objectives included efficacy assessments, pharmacokinetic (PK), pharmacodynamic (PD) and correlative biomarker evaluation.

Results: As of June 17, 2026, data cutoff, 32 pts have been treated with HC-7366 monotherapy: 6 at 20 mg, 4 at 30 mg, 13 at 40 mg, 5 at 50 mg and 4 at 60 mg, including backfill slots. The 60 mg cohort is currently enrolling. Median age was 66 yrs (range 46-71), median prior lines of therapy were 3 (range, 1-9) with 97% post-VEN failure and 41% post-transplant. 56% pts had TP53mut and 16% had AEL or erythroid differentiated AML. Of the 32 patients enrolled, 24 were evaluable for efficacy.

Treatment emergent adverse events (TEAEs) of any grade occurred in 97% pts, and grade ≥3 TEAEs occurred in 69% mostly related to underlying AML. Most common TEAEs of any grade were hypokalemia (72%; grade ≥3, 28%), diarrhea (56%; grade 3, 6%), increased AST (50%; grade 3, 13%), increased ALT (44%; grade 3, 9%), and hyponatremia (34%). The most common treatment-related AEs reported in more than two patients were diarrhea (39%; grade 3, 3%), increased ALT (16%), increased AST (13%; grade 3, 3%) and QTc prolongation (7%). Two dose limiting toxicities (DLTs) were observed: 1 grade 3 diarrhea in the 40 mg cohort and 1 grade 3 ALT elevation in the 60 mg cohort. There were no treatment-related deaths.

HC-7366 demonstrated dose-dependent bone marrow (BM) blast reductions with 41% (7/17) of efficacy-evaluable patients at 40 to 60 mg doses achieving >50% blast reduction. Objective responses of CRi/MLFS occurred in 2 TP53-mutated pts with 1 pt transitioning to allogeneic SCT.

PK and PD analyses demonstrated a positive correlation between HC-7366 drug exposure and systemic ISR biomarkers, as well as an increased blast-specific expression of the ISR/GCN2 downstream marker CD98 (p=0.012). HC-7366 exposure was also correlated with a reduction in BM blasts after treatment (p=0.0009), demonstrating both exposure-dependent pathway activation and anti-leukemic activity. Longitudinal single-cell mass cytometry (CyTOF) on serial samples from 17 pts showed coordinated apoptotic reprogramming, depletion of CD34⁺/CD33⁺ LSCs, and broad remodeling of intracellular signaling networks.

Conclusion: Harnessing p53-independent cell death via ISR activation using HC-7366 showed tolerable safety with clinical and pharmacodynamic activity in profoundly high-risk R/R AML. Blast reductions and responses were noted in VEN-refractory pts with TP53mut, complex karyotype, and erythroid biology, which are highly refractory populations with high unmet need. Single cell analysis showed coordinated apoptotic reprograming and depletion of LSCs. The trial continues to enroll, with Fast Track Designation for HC-7366, and future plans for azacitidine-venetoclax triplet cohort.

Dany Nassar, MD: No relevant conflicts of interest to declare.